IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced ...

Emrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ...

The Macau Special Administrative Region (ISAF) Pharmaceutical Administration Bureau has approved IASO Biotherapeutics’ new ...

This is the first NDA approval for Equecabtagene Autoleucel outside Mainland China. Equecabtagene Autoleucel (trade name: FUCASO) was approved by China's National Medical Products Administration ...

The Lok Sabha will take up the contentious Waqf (Amendment) Bill for discussion and passage today. NDA backed parties ...

Vanda Pharmaceuticals (VNDA) announced that a New Drug Application was submitted to the U.S. FDA requesting marketing approval of Bysanti for ...

Milestone Pharmaceuticals' stock drops over 61% after receiving a Complete Response Letter from the FDA for its CARDAMYST NDA ...

Such risks and uncertainties include, among other things, assumptions regarding the sufficiency of clinical data to support NDA approval of tazemetostat for the treatment of patients with follicular ...